Michael Torres focuses on innovation at the intersection of technology, medicine, and healthcare delivery. His coverage spans medical devices, digital health, diagnostics, and emerging care models. At The Catalyst Brief, Michael evaluates how new tools translate from concept to real-world impact, considering clinical evidence, adoption challenges, and broader industry implications.
129 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Medical TechnologyA persistent gap in telehealth adoption between rural and non-rural populations raises fresh questions about equitable digital health access. This new report illuminates the scale of the problem—and spotlights the challenges ahead for policymakers, providers, and technology innovators.
Michael TorresAug 4, 2026
Healthcare InvestmentHealth technology companies drew significant attention in July 2026, with several large funding rounds announced that reflect both market optimism and the growing demand for transformative medical solutions. This roundup explores the most notable health tech deals, contextualizes their significance within broader industry trends, and examines what these investments could mean for patients, providers, and stakeholders.
Michael TorresAug 2, 2026
Regulatory & PolicyWith new leadership nominees advancing and persistent gaps in infectious disease monitoring, U.S. health agencies face the twin challenges of maintaining readiness and driving reform. Federal statements point to recognition of existing limitations and provide insight into evolving health policy priorities.
Michael TorresAug 1, 2026
Biopharmaceutical IndustryBristol Myers Squibb (BMS) has reported exceptionally strong quarterly financial results, prompting an upward revision of its 2026 outlook. However, these achievements face significant headwinds due to further delays in pivotal clinical data for Cobenfy, the company’s high-profile Alzheimer’s candidate, and a rescheduled readout for the cardiovascular drug milvexian. As BMS navigates these developments, industry observers are debating how execution risks and shifting clinical timelines might impact its market trajectory and R&D pipeline resilience.
Michael TorresJul 30, 2026
Regulatory & PolicyProposed new limits on the duration of visas for international graduate students and postdoctoral researchers are raising alarm bells for the future of U.S. science. Policy experts caution that these restrictions could have lasting repercussions on American competitiveness and innovation.
Michael TorresJul 28, 2026
Biotech InnovationThe pursuit of safer treatment options for Alzheimer’s disease—particularly those targeting amyloid—has reached another milestone. Preliminary results from ProMIS Neurosciences highlight the delicate balance between efficacy and safety and may provide new optimism for both clinicians and patients seeking effective interventions.
Michael TorresJul 28, 2026
Biotech InnovationAlpha-1 antitrypsin deficiency (AATD) was once seen by drug developers as a therapeutic dead end. New genetic tools and emerging industry trends have transformed it into one of biopharma’s hottest battlegrounds, with rapid-fire innovation, complex legal maneuvering, and high-stakes international competition.
Michael TorresJul 28, 2026
Biopharmaceutical IndustryA growing number of Americans living with diabetes face uncertainty as the widely-used Lantus Solostar insulin pen appears increasingly difficult to obtain. This development comes in the wake of other insulin pens leaving the market, squeezing supply and raising questions about access, manufacturing resilience, and the impact on patient care. As advocates and policymakers watch closely, the situation underscores vulnerabilities within the medication supply chain for one of the world’s most essential drugs.
Michael TorresJul 23, 2026
Healthcare InvestmentThe biotech IPO wave of 2026 has been characterized by a surge of newly public companies seeking fresh capital and visibility in a rapidly evolving healthcare sector. As BioSpace launches its IPO tracker, stakeholders gain critical insight into which companies are thriving—and which are facing early growing pains—in the unforgiving public markets.
Michael TorresJul 22, 2026
Biopharmaceutical IndustryWomen’s oncology is on track to become a $110 billion market by 2030, highlighting vast opportunities for innovation and care improvement. However, a recent report spotlights persistent disparities in both funding and access, revealing the critical areas where stakeholders must focus to ensure growth benefits translate to better outcomes.
Michael TorresJul 20, 2026
Regulatory & PolicyAs artificial intelligence extends deeper into manufacturing processes, the U.S. Food and Drug Administration has issued its first cGMP warning letter focused specifically on AI-generated activities. This action sets a precedent for how AI should be integrated and regulated within existing quality systems.
Michael TorresJul 16, 2026
Biopharmaceutical IndustryIn a move reflecting the growing importance of the China-to-global innovation pipeline, AstraZeneca will pay $600 million upfront for worldwide rights to Zegfrovy, adding to its lung cancer portfolio and boosting Dizal’s international ambitions. This deal represents another significant step in cross-border biopharma partnerships as licensing agreements shape the future of oncology therapeutics.
Michael TorresJul 14, 2026